IN2014DN06580A - - Google Patents
Info
- Publication number
- IN2014DN06580A IN2014DN06580A IN6580DEN2014A IN2014DN06580A IN 2014DN06580 A IN2014DN06580 A IN 2014DN06580A IN 6580DEN2014 A IN6580DEN2014 A IN 6580DEN2014A IN 2014DN06580 A IN2014DN06580 A IN 2014DN06580A
- Authority
- IN
- India
- Prior art keywords
- compounds
- present
- relates
- stent
- thrombosis
- Prior art date
Links
- 208000007536 Thrombosis Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010002388 Angina unstable Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 208000007814 Unstable Angina Diseases 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000002399 angioplasty Methods 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 238000007631 vascular surgery Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261587030P | 2012-01-16 | 2012-01-16 | |
| PCT/US2013/021749 WO2013109632A2 (en) | 2012-01-16 | 2013-01-16 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN06580A true IN2014DN06580A (de) | 2015-05-22 |
Family
ID=48799805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN6580DEN2014 IN2014DN06580A (de) | 2012-01-16 | 2013-01-16 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9303044B2 (de) |
| EP (1) | EP2804610B1 (de) |
| CN (1) | CN104936598B (de) |
| AU (1) | AU2013209884C1 (de) |
| CA (1) | CA2861350C (de) |
| DK (1) | DK2804610T3 (de) |
| ES (1) | ES2708201T3 (de) |
| IN (1) | IN2014DN06580A (de) |
| WO (1) | WO2013109632A2 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008057601A2 (en) | 2006-11-08 | 2008-05-15 | The Rockefeller University | Organic compounds |
| CA2805724A1 (en) * | 2010-07-16 | 2012-01-19 | Rockefeller University | Oxadiazolo[3,2-a]pyrimidines and thiadiazolo[3,2-a]pyrimidines |
| US11684622B2 (en) | 2018-06-19 | 2023-06-27 | Celecor Therapeutics, Inc. | Deuterated RUC-4 |
| KR20230005210A (ko) * | 2020-04-08 | 2023-01-09 | 레믹스 테라퓨틱스 인크. | 스플라이싱을 조절하기 위한 화합물 및 방법 |
| MX2023009620A (es) * | 2021-02-17 | 2023-11-01 | Celecor Therapeutics Inc | Metodos terapeuticos. |
| WO2022177962A1 (en) * | 2021-02-17 | 2022-08-25 | Celecor Therapeutics, Inc. | Stable ruc-4 formulations |
| WO2023064879A1 (en) * | 2021-10-13 | 2023-04-20 | Remix Therapeutics Inc. | Compounds and methods for modulating nucleic acid splicing |
| WO2026019771A1 (en) | 2024-07-15 | 2026-01-22 | Celecor Therapeutics, Inc. | Zalunfiban for use in the treatment of thrombotic disorder in patients with renal impairment |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2823686A1 (de) | 1978-05-31 | 1979-12-06 | Bayer Ag | Imidazo eckige klammer auf 2.1-b eckige klammer zu eckige klammer auf 1.3.4 eckige klammer zu -thiadiazole |
| US4548938A (en) * | 1981-07-15 | 1985-10-22 | Janssen Pharmaceutica N.V. | 5-H-1,3,4-thiadiazolo[3,2-a]pyrimidin-5-one compounds |
| WO2008057601A2 (en) | 2006-11-08 | 2008-05-15 | The Rockefeller University | Organic compounds |
| WO2009024615A1 (en) | 2007-08-23 | 2009-02-26 | Novartis Ag | Aminobenzyl-substituted cyclic sulfones useful as bace inhibitors |
| CA2805724A1 (en) * | 2010-07-16 | 2012-01-19 | Rockefeller University | Oxadiazolo[3,2-a]pyrimidines and thiadiazolo[3,2-a]pyrimidines |
-
2013
- 2013-01-16 EP EP13738252.9A patent/EP2804610B1/de active Active
- 2013-01-16 IN IN6580DEN2014 patent/IN2014DN06580A/en unknown
- 2013-01-16 CA CA2861350A patent/CA2861350C/en active Active
- 2013-01-16 US US14/372,488 patent/US9303044B2/en active Active
- 2013-01-16 ES ES13738252T patent/ES2708201T3/es active Active
- 2013-01-16 AU AU2013209884A patent/AU2013209884C1/en active Active
- 2013-01-16 CN CN201380010564.7A patent/CN104936598B/zh active Active
- 2013-01-16 DK DK13738252.9T patent/DK2804610T3/en active
- 2013-01-16 WO PCT/US2013/021749 patent/WO2013109632A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN104936598B (zh) | 2017-11-03 |
| CA2861350A1 (en) | 2013-07-25 |
| AU2013209884A1 (en) | 2014-08-07 |
| CN104936598A (zh) | 2015-09-23 |
| EP2804610A4 (de) | 2016-04-20 |
| EP2804610B1 (de) | 2018-10-31 |
| US20150050325A1 (en) | 2015-02-19 |
| EP2804610A2 (de) | 2014-11-26 |
| AU2013209884B2 (en) | 2017-06-29 |
| CA2861350C (en) | 2020-12-15 |
| DK2804610T3 (en) | 2019-02-25 |
| AU2013209884C1 (en) | 2018-01-18 |
| AU2013209884A8 (en) | 2014-08-14 |
| ES2708201T3 (es) | 2019-04-09 |
| US9303044B2 (en) | 2016-04-05 |
| WO2013109632A3 (en) | 2015-06-18 |
| WO2013109632A2 (en) | 2013-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN06580A (de) | ||
| IN2014DN11157A (de) | ||
| WO2008057601A3 (en) | Organic compounds | |
| GEP20156285B (en) | Compounds and compositions as trk inhibitors | |
| IN2014CN02515A (de) | ||
| NZ730134A (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| PH12016501600A1 (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| PH12014502757B1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| MX2014000779A (es) | Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide. | |
| PH12014501979A1 (en) | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor | |
| PH12017500841B1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| MX2014015197A (es) | Tratamiento y prevencion de la enfermedad cardiovascular y trombosis. | |
| IN2014MN00697A (de) | ||
| MX2015014083A (es) | Inhibidores de enzima de escision de proteina precursora beta-amiloide (app) en el sitio beta 1 (bace1). | |
| HK1205506A1 (en) | Protein kinase inhibitors | |
| MX2012001134A (es) | Composiciones y metodos para inhibicion de la via jak. | |
| PH12013500644A1 (en) | Co-crystals and salts of ccr3-inhibitors | |
| MY166449A (en) | Pharmaceutical composition of rosuvastatin calcium | |
| WO2014055967A3 (en) | Compositions and methods for treating diseases of protein aggregation involving ic3b deposition | |
| MX2015000618A (es) | Derivados de di- y tri-heteroarilo como inhibidores de la agregacion de proteinas. | |
| MX2012006778A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno. | |
| NZ707773A (en) | Methods of treating liver diseases | |
| PH12018500433A1 (en) | Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same | |
| IN2014DN03010A (de) | ||
| TN2015000021A1 (en) | Use of vegfr-3 inhibitors for treating hepatocellular carcinoma |